Do Cancer Drugs Trigger Skin Issues?
November 26, 2024
-
2 min
The Food and Drug Administration's Adverse Event Reporting System revealed that approximately 50% of significant dermatologic adverse events associated with anticancer therapies are linked to targeted therapies. The study, encompassing over 3 million reports, highlighted the most frequently reported adverse events, including rash, dry skin, alopecia, and inflammatory conditions. Additionally, newer therapies like enfortumab vedotin showed a notable percentage of skin-related adverse events. The findings, published in the Journal of the American Academy of Dermatology, underscore the importance of monitoring dermatologic adverse events to enhance clinical decision-making and post-marketing surveillance.
1. Nearly 50% of significant dermatologic adverse events associated with anticancer therapies are linked to targeted therapies. 2. Rash, dry skin, alopecia, and inflammatory conditions were the most frequently reported adverse events. 3. Enfortumab vedotin, a newer therapy, showed a notable percentage of skin-related adverse events. 4. The study was published in the Journal of the American Academy of Dermatology. 5. Fisher’s exact test and the Bonferroni correction were employed to ensure statistical validity.
Listen Tab content
